Medicalgorithmics (LTS:0QR8) ROCE %: -4.09% (As of Mar. 2026)

What is Medicalgorithmics ROCE %?

Medicalgorithmics LTS:0QR8 71 ROCE % is -4.09% as of Mar. 2026. GuruFocus rates LTS:0QR8 with a GF Score™ of 71/100 and a GF Value™ of zł31.62. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Medicalgorithmics's annualized ROCE % for the quarter that ended in Mar. 2026 was -4.09%.

Medicalgorithmics (LTS:0QR8) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Medicalgorithmics ROCE % Related Terms

Medicalgorithmics ROCE % Historical Data

* Premium members only.

The historical data trend for Medicalgorithmics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medicalgorithmics ROCE % Chart

Medicalgorithmics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

-3.99

27.47

-0.12

-15.15

-10.06

Medicalgorithmics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-17.50	-7.59	-13.46	-1.64	-4.09

71GF Score

Medicalgorithmics SA LTS:0QR8

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Medicalgorithmics ROCE % Calculation

Medicalgorithmics's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	-9.658	/	( ( (105.814 - 8.967)	+	(108.233 - 12.987) )	/ 2 )
	=	-9.658	/	( (96.847	+	95.246)	/ 2 )
	=	-9.658	/	96.0465
	=	-10.06 %

Medicalgorithmics's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	-3.912	/	( ( (108.233 - 12.987)	+	(111.359 - 15.52) )	/ 2 )
	=	-3.912	/	( ( 95.246	+	95.839 )	/ 2 )
	=	-3.912	/	95.5425
	=	-4.09 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of -4.09% mean?

Medicalgorithmics (LTS:0QR8) has a ROCE % of -4.09% as of Mar. 2026.

Is Medicalgorithmics' ROCE % too high?

Medicalgorithmics' current ROCE % is -4.09%. Overall, Medicalgorithmics has a GF Score™ of 71/100, reflecting its overall financial health beyond just this single metric.

How does Medicalgorithmics' ROCE % compare to ABT and SYK?

Medicalgorithmics' ROCE % of -4.09% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Medical Devices & Instruments company?

The median ROCE % among Medical Devices & Instruments companies is 2.20, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicalgorithmics's current ROCE % is -4.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Medicalgorithmics stock overvalued right now?

Medicalgorithmics (LTS:0QR8) has a current ROCE % of -4.09%. The stock's GF Value™ is zł31.62, compared to a current price of zł33.07 — trading 4.6% above its estimated fair value. The current ROCE % is -4.09%. Medicalgorithmics' overall GF Score™ is 71/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Medicalgorithmics (LTS:0QR8), the current ROCE % is -4.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medicalgorithmics (LTS:0QR8) Overvalued in 2026?

Based on GuruFocus' analysis, Medicalgorithmics stock appears to be overvalued. The current stock price of zł33.07 is trading 4.6% above its estimated GF Value™ of zł31.62.

Key valuation signals for LTS:0QR8:

ROCE %: -4.09%
GF Value™: zł31.62 vs. price of zł33.07 (4.6% above fair value)
GF Score™: 71/100 with 4 warning signs

No single metric tells the full story. See the LTS:0QR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medicalgorithmics Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies WAR:GMT WAR:AME WAR:MTN WAR:NST WAR:GMZ WAR:SDS WAR:INM WAR:MSM WAR:CMI WAR:ADV ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Other Exchanges MDG:Poland

Address Al Jerozolimskie 81, 19 Floor, Central Tower Building, Warsaw, POL, 02-001

Website http://www.medicalgorithmics.com

Medicalgorithmics SA is a medical technology company. It is engaged in the development of Digital Signal Processing (DSP) algorithms development and software and hardware electronics design for medical applications. The company specializes in providing advance technological solutions in the field of cardiac diagnostics, with a particular focus on ECG signal analysis. The group concentrates on the production and development of its flagship product Pocket ECG - a system for remote monitoring of cardiac arrhythmias. The offered solutions include algorithms and diagnostic systems used in remote heart monitoring. The company operates in Poland, the USA, and other, with majority of revenue from the USA.

71GF Score

Get the complete analysis for LTS:0QR8

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł33.07

Price

zł31.62

GF Value

View LTS:0QR8 Analysis

See ROCE % data for all stocks →